An in vivo patient-derived model of endogenous IDH1-mutant glioma.


Somatic mutations in the catalytic domain of isocitrate dehydrogenase (IDH) 1/2 and accumulation of the oncometabolite 2-hydroxyglutarate (2-HG) appear to be among the earliest events in gliomagenesis and may contribute to malignant transformation. The lack of cell lines with endogenous mutations has been one of the major challenges in studying IDH1/2… (More)
DOI: 10.1093/neuonc/nor207


4 Figures and Tables